These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 6933346)
1. Oral contraception and thromboembolism: the role of progestogens. N Z Med J; 1980 Aug; 92(665):98, 101. PubMed ID: 6933346 [TBL] [Abstract][Full Text] [Related]
3. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study. Hannaford PC; Kay CR Br J Gen Pract; 1998 Oct; 48(435):1657-62. PubMed ID: 10071398 [TBL] [Abstract][Full Text] [Related]
6. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12". Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253 [TBL] [Abstract][Full Text] [Related]
7. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel? Meurer LN; Slawson JG J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554 [No Abstract] [Full Text] [Related]
8. [Influence of progestins on adverse effects of oral contraceptives]. Wynn V Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210 [TBL] [Abstract][Full Text] [Related]
9. Estrogen dose in oral contraceptives: FDA committee examines safety and utility of 50 mcg estrogen OCs. Contracept Rep; 1994 Mar; 5(1):10-3. PubMed ID: 12287738 [TBL] [Abstract][Full Text] [Related]
10. Thromboembolic disease and the steroidal content of oral contraceptives. Swyer GI Res Reprod; 1970 Jul; 2(4):1. PubMed ID: 12254979 [TBL] [Abstract][Full Text] [Related]
11. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323 [TBL] [Abstract][Full Text] [Related]
12. Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study. Kay CR Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):762-5. PubMed ID: 6801981 [TBL] [Abstract][Full Text] [Related]
13. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Jick SS; Kaye JA; Russmann S; Jick H Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485 [TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risks of oral contraceptives: dose-response relationship]. Kelleher CC Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220 [TBL] [Abstract][Full Text] [Related]
15. Oral contraception: past, present, and future perspectives. Mishell DR Int J Fertil; 1991; 36 Suppl 1():7-18. PubMed ID: 1678381 [TBL] [Abstract][Full Text] [Related]
16. Thrombosis and the Pill. Vessey MP Prescr J; 1970 Feb; 10(1):1-7. PubMed ID: 12254686 [TBL] [Abstract][Full Text] [Related]
17. [Hormonal contraception and substitution therapy: the importance of progestogen for cardiovascular diseases]. Kuhl H Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):653-62. PubMed ID: 1452000 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception; 1998 May; 57(5):315-24. PubMed ID: 9673838 [TBL] [Abstract][Full Text] [Related]